WellDyne Spotlights Pharmacy Benefit Innovation at PBMI Conference

WellDyne is proud to announce that Nick Page, Chief Clinical Officer, will take the stage at the upcoming PBMI Annual National Conference. He will join a panel of industry experts to explore how strategies can evolve to balance affordability, access and clinical outcomes in the session: Pharmacy Benefit Innovation in Autoimmune Disease: Balancing Access, Cost, and Complexity.

Autoimmune therapies are among the fastest-growing drivers of pharmacy spend. While biosimilars were positioned as a breakthrough solution, plan sponsors have yet to realize the full promise of savings. Rebate-driven models, shifting prescribing patterns and high-frequency dosing have kept costs stubbornly high. “The rebate game isn’t working for plan sponsors or patients,” says Nick. “We need evidence-based, clinically aligned approaches that put value and outcomes ahead of rebates.”

WellDyne takes a different approach by prioritizing lowest net cost strategies that move beyond rebates. From targeted utilization management to precision medicine and smarter specialty pharmacy solutions, WellDyne helps plan sponsors improve affordability while ensuring members receive the right therapy at the best cost.

The PBMI panel will highlight practical strategies including biosimilar adoption, formulary innovation and digital engagement that help plan sponsors manage rising complexity and achieve better outcomes.

Session Details:
Pharmacy Benefit Innovation in Autoimmune Disease: Balancing Access, Cost, and Complexity
PBMI Annual National Conference
Friday, September 5, 11:10-11:55 am ET